Expressing Recombinant Hormone Or Growth Factor Patents (Class 435/360)
  • Patent number: 9051356
    Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: June 9, 2015
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Löffler, Lars Stöckl
  • Publication number: 20150148291
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: November 26, 2014
    Publication date: May 28, 2015
    Inventors: UDI EYAL FIMA, GILI HART
  • Publication number: 20150126445
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
    Type: Application
    Filed: December 10, 2014
    Publication date: May 7, 2015
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Publication number: 20150093358
    Abstract: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also discarded.
    Type: Application
    Filed: November 26, 2014
    Publication date: April 2, 2015
    Inventors: FUAD FARES, UDI EYAL FIMA
  • Publication number: 20150079063
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Application
    Filed: May 9, 2014
    Publication date: March 19, 2015
    Applicant: OPKO Biologics Ltd.
    Inventors: Udi Eyal FIMA, Gili Hart
  • Publication number: 20150072932
    Abstract: The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.
    Type: Application
    Filed: April 9, 2013
    Publication date: March 12, 2015
    Inventors: Geraldine Siegfried, Abdel-Majid Khatib
  • Publication number: 20150072924
    Abstract: This invention is directed to a chorionic gonadotrophin carboxy terminal peptide (CTP) modified dual GLP-1/Glucagon receptor agonist, and methods of producing and using the same. In one embodiment, the present invention provides a CTP-modified polypeptide comprising a dual GLP-1/Glucagon receptor agonist and at least one chorionic gonadotrophin carboxy terminal peptide (CTP) attached to the amino terminus or carboxy terminus of said agonist.
    Type: Application
    Filed: April 17, 2013
    Publication date: March 12, 2015
    Applicant: OPKO Biologics Ltd.
    Inventors: Udi Eyal Fima, Oren Hershkovitz
  • Publication number: 20150064157
    Abstract: The present invention provides further improved compositions and methods for efficient lysosomal targeting based on the GILT technology. Among other things, the present invention provides methods and compositions for targeting lysosomal enzymes to lysosomes using furin-resistant lysosomal targeting peptides. The present invention also provides methods and compositions for targeting lysosomal enzymes to lysosomes using a lysosomal targeting peptide that has reduced or diminished binding affinity for the insulin receptor.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Jonathan H. LeBowitz, John Maga
  • Patent number: 8932828
    Abstract: The present invention relates to novel methods for making and refolding insoluble or aggregated proteins having free cysteines in which a host cell expressing the protein is exposed to a cysteine blocking agent. The soluble, refolded proteins produced by the novel methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form PEGylated proteins.
    Type: Grant
    Filed: September 29, 2010
    Date of Patent: January 13, 2015
    Assignee: Bolder Biotechnology, Inc.
    Inventors: Mary S. Rosendahl, George N. Cox, Daniel H. Doherty
  • Publication number: 20140356326
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Application
    Filed: December 10, 2013
    Publication date: December 4, 2014
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
  • Publication number: 20140336367
    Abstract: The present invention provides a method and system for producing a NELL protein. The method and system comprise a CELL encoding a NELL protein or peptide and a non-insect secretory signal peptide.
    Type: Application
    Filed: February 15, 2013
    Publication date: November 13, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kang Ting, Chia Soo
  • Publication number: 20140323401
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 30, 2014
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN
  • Publication number: 20140256621
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.
    Type: Application
    Filed: July 3, 2012
    Publication date: September 11, 2014
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Caroline Ekbland, Jonathan David Roth
  • Publication number: 20140235535
    Abstract: Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.
    Type: Application
    Filed: July 3, 2012
    Publication date: August 21, 2014
    Inventors: Mary Erickson, David C. Litzinger, Soumitra S. Ghosh, Zijian Guo, Manoj P. Samant, Abhinandini Sharma, Lala Mamedova, Esther Odile Levy, Caroline Ekblad
  • Patent number: 8809499
    Abstract: Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: August 19, 2014
    Assignee: Chongqing Fagen Biomedical Inc.
    Inventors: Kai Fan, Zhiquan Zhao, Chun Zhang, Yong Chen, Hua Luo, Li Yang, Honghong Liu
  • Publication number: 20140206758
    Abstract: The present invention provides methods of improving the levels and stability of expression of interleukin-12 family cytokine polypeptides by expressing the alpha and beta subunits of the polypeptides at their determined relative molar ratios that increase the levels and stability of expression of the heterodimer, e.g., in comparison to heterodimer expressed at an equimolar ratio.
    Type: Application
    Filed: April 3, 2014
    Publication date: July 24, 2014
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: Barbara K. Felber, George N. Pavlakis
  • Publication number: 20140171625
    Abstract: The invention provides novel polypeptides having at least one biological activity of cardiotrophin and improved biologic drug-like properties, and polynucleotides encoding the polypeptides of the invention. The polypeptides of the invention can be used therapeutically, such as, for example, in methods of tissue regeneration.
    Type: Application
    Filed: February 1, 2012
    Publication date: June 19, 2014
    Applicant: Fate Therapeutics, Inc.
    Inventors: Tom Tong Lee, Kevin Lai, John Mendlein, Peter Flynn
  • Publication number: 20140155290
    Abstract: Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided.
    Type: Application
    Filed: February 6, 2014
    Publication date: June 5, 2014
    Applicant: AMGEN INC.
    Inventor: Christopher Kenyon Crowell
  • Publication number: 20140154214
    Abstract: GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an increased small intestine/colon and stomach/colon selectivity. More particularly, preferred GLP-2 analogues disclosed herein comprise substitutions at one or more of positions 11, 16, 20, 24 and/or 28 of the wild-type GLP-2 sequence, optionally in combination with further substitutions at position 2 and one or more of positions 3, 5, 7, and 10, and/or a deletion of one or more of amino acids 31 to 33 and/or the addition of a N-terminal or C-terminal stabilizing peptide sequence. The analogues are particularly useful for the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy.
    Type: Application
    Filed: February 4, 2014
    Publication date: June 5, 2014
    Inventors: Bjarne Due LARSEN, Yvette Miata Petersen
  • Publication number: 20140148390
    Abstract: The present invention provides Relaxin fusion proteins, wherein a linker connects the carboxy-terminus of Relaxin with a proteinaceous half-life extending moiety and the linker comprises a protease cleavage site. Therefore, the invention provides Relaxin fusion polypeptides with extended half-life whereby the fusion protein by itself serves as a depot for release of the biologically active Relaxin. Furthermore, the invention provides nucleic acid sequences encoding the foregoing fusion polypeptides, vectors containing the same, cells expressing the Relaxin fusion polypeptides, pharmaceutical compositions and medical use of such fusion polypeptides.
    Type: Application
    Filed: July 4, 2012
    Publication date: May 29, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ulrich Haupts, Andreas Wilmen
  • Patent number: 8722399
    Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: May 13, 2014
    Assignee: Loma Linda University
    Inventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
  • Publication number: 20140121153
    Abstract: The present invention relates to an isolated polypeptide comprising (a) the amino acid sequence set forth in SEQ ID NO: 21; or (b) an amino acid sequence that is at least 95% identical to SEQ ID NO: 21, and to therapeutic treatments based thereon.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 1, 2014
    Inventors: Tamara SANDLER, Orly DEVARY
  • Publication number: 20140105896
    Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
    Type: Application
    Filed: September 12, 2013
    Publication date: April 17, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Sharon CLOAD, Linda ENGLE, Dasa LIPOVSEK, Malavi MADIREDDI, Ginger Chao RAKESTRAW, Joanna SWAIN, Wenjun ZHAO
  • Publication number: 20140099280
    Abstract: The present invention discloses novel active polypeptide fragments of human IL-33 corresponding to natural forms generated by the proteases of human neutrophils (cathepsin G, elastase 2, proteinase 3), as well as the use thereof as a drug, in particular for the treatment of infectious diseases, inflammatory diseases, atherosclerosis, cardiovascular diseases, obesity, or cancer.
    Type: Application
    Filed: February 24, 2012
    Publication date: April 10, 2014
    Applicant: Cenre National De La Recherche Scientifique
    Inventors: Jean-Philippe Girard, Corinne Cayrol-Girard, Emma Lefraancais
  • Patent number: 8669104
    Abstract: Gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages. Gene-modified, inflammation-specific macrophages that comprise a 1-alpha-hydroxylase gene. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, inflammation-specific monocytes that comprise a 1-alpha-hydroxylase gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme when the monocytes transdifferentiate into gene-modified, inflammation-specific macrophages.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: March 11, 2014
    Assignee: Loma Linda University
    Inventors: David J. Baylink, Kin-Hing William Lau, Xuezhong Qin
  • Publication number: 20140005109
    Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.
    Type: Application
    Filed: January 13, 2012
    Publication date: January 2, 2014
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Tonia S. Rex, Timothy A. Sullivan
  • Publication number: 20130336926
    Abstract: The present invention provides compositions and methods relating to IL-1Rrp2 requiring proteins.
    Type: Application
    Filed: June 11, 2013
    Publication date: December 19, 2013
    Applicant: Amgen Inc.
    Inventors: John E. SIMS, Blair R. RENSHAW, Christopher GABEL, Jennifer E. TOWNE, Randal R. KETCHEM
  • Patent number: 8563303
    Abstract: The present invention relates to the field of cell culture technology and relates to methods of replicating/cloning cells, preferably cell lines which are important for the production of biopharmaceuticals. The invention also relates to methods of preparing proteins using cells that have been obtained and replicated by single cell deposition and compositions which make it possible to replicate individual cells. By using IGF particularly in conjunction with HSA in the culture medium after recloning, the recloning efficiency and hence the quantity of clones obtained can be increased significantly.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: October 22, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Jüergen Fieder, Lore Florin, Hitto Kaufmann, Thomas Krieg, Melanie Briegel
  • Publication number: 20130236959
    Abstract: Thermostable FGF-2 proteins having enhanced ability to support human pluripotent stem cell cultures are provided. Also provided are methods and compositions utilizing thermostable FGF-2 proteins.
    Type: Application
    Filed: December 17, 2012
    Publication date: September 12, 2013
    Inventors: Guokai Chen, James A. Thomson, Zhonggang Hou
  • Patent number: 8530190
    Abstract: The invention relates to analogs of glycoprotein hormones with an intersubunit disulfide crosslink and their preparation and use. Corresponding DNA sequences and host cells, as well as pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: June 25, 1998
    Date of Patent: September 10, 2013
    Assignee: Merck Serono SA
    Inventor: William R. Moyle
  • Publication number: 20130203617
    Abstract: Disclosed are a glycoprotein analysis kit and use thereof. The glycoprotein analysis kit comprises a fluorescently labeled antibody, a fluorescently labeled biomaterial, and a support, and is used in a dual probing method for analyzing the content of a glycoprotein and profiling the oligosaccharide chain, simultaneously, and a method for selecting a single cell producing the glycoprotein having a desired glycosylation pattern. Also, a single cell producing the glycoprotein having a desired glycosylation pattern is provided.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 8, 2013
    Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Hak Sung Kim, Sun Young Park, Sang Chul Lee, Eun Kyoung Kim, Sung Ho Kim, Wan Jung Kim, Yong Tae Kim, Young Dok Son, Jung Hoe Kim
  • Publication number: 20130196909
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relate to methods of making and using the truncated growth factors.
    Type: Application
    Filed: March 24, 2011
    Publication date: August 1, 2013
    Applicant: LIFENET HEALTH
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
  • Publication number: 20130196910
    Abstract: The invention relates to truncated growth factors and variants thereof. The invention also relates to methods of making and using the truncated growth factors.
    Type: Application
    Filed: March 24, 2011
    Publication date: August 1, 2013
    Applicant: LIFENET HEALTH
    Inventors: Xiaofei Qin, Silvia Chen, Jingsong Chen, James Clagett
  • Publication number: 20130143949
    Abstract: A polypeptide comprising a G-CSF domain operably linked to a Tf domain, wherein the ability of the polypeptide to be transported into a cell expressing a TfR gene or the ability of the polypeptide to be transported across a cell expressing a TfR gene via transcytosis is higher than that of the G-CSF domain alone.
    Type: Application
    Filed: May 1, 2012
    Publication date: June 6, 2013
    Applicants: NATIONAL INSTITUTE OF HEALTH
    Inventors: Wei-Chiang SHEN, Yun BAI, David ANN, Adam WIDER
  • Publication number: 20130122004
    Abstract: The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders.
    Type: Application
    Filed: January 17, 2013
    Publication date: May 16, 2013
    Applicant: NOVARTIS AG
    Inventor: Novartis AG
  • Publication number: 20130023474
    Abstract: The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 24, 2013
    Applicant: NGM Biopharmaceuticals, Inc.
    Inventors: LEI LING, DARRIN A. LINDHOUT
  • Publication number: 20130023477
    Abstract: We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 24, 2013
    Inventors: Richard Ross, Peter Artymiuk, Jon Sayers
  • Publication number: 20120322735
    Abstract: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.
    Type: Application
    Filed: August 22, 2012
    Publication date: December 20, 2012
    Inventors: Peter Artymiuk, Richard A. Ross, Jon Sayers
  • Publication number: 20120316114
    Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
    Type: Application
    Filed: May 8, 2012
    Publication date: December 13, 2012
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
  • Patent number: 8329429
    Abstract: The present invention provides a method of enhanced protein production that comprises the step of expressing a recombinant gene encoding the protein in eukaryotic cells under conditions in which cleavage of the pro-domain of the protein is inhibited or eliminated. Generally the method of the present invention includes the step of inhibiting or altering the cleavage of a pro-domain of a recombinant protein of interest in order to increase the amount of recombinant protein secreted from a eukaryotic cell. Recombinant proteins that can be prepared using the method of this invention include members of the transforming growth factor-? (TGF-?) superfamily, such as bone morphogenetic proteins. Also provided are genetically engineered cells and polynucleotides for performing the method of the invention.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: December 11, 2012
    Assignee: Induce Biologics Inc.
    Inventors: Sean A. F. Peel, Cameron M. L. Clokie, Jeffrey D. Turner
  • Publication number: 20120301921
    Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
    Type: Application
    Filed: April 3, 2012
    Publication date: November 29, 2012
    Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
  • Publication number: 20120264686
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: October 18, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Publication number: 20120252726
    Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.
    Type: Application
    Filed: April 11, 2011
    Publication date: October 4, 2012
    Applicant: NSGENE A/S
    Inventors: Teit E. Johansen, Nikolaj Blom, Claus Hansen
  • Publication number: 20120238496
    Abstract: Provided is a fusion protein, which comprises human fibroblast growth factor 21 and glucagon-like-peptide-1 or its analogs. Also provided is the medicament composition comprising the fusion protein, which can be used for treating or preventing obesity, diabetes, hyperglycemia and hyperlipidemia etc.
    Type: Application
    Filed: March 12, 2010
    Publication date: September 20, 2012
    Applicant: Chongqing Fagen Biomedical Inc.
    Inventors: Kai Fan, Zhiquan Zhao, Chun Zhang, Yong Chen, Hua Luo, Li Yang, Honghong Liu
  • Publication number: 20120230947
    Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
    Type: Application
    Filed: April 4, 2012
    Publication date: September 13, 2012
    Applicant: AMUNIX OPERATING INC.
    Inventors: VOLKER SCHELLENBERGER, WILLEM P. STEMMER, CHIA-WEI WANG, MICHAEL D. SCHOLLE, MIKHAIL POPKOV, NATHANIEL C. GORDON, ANDREAS CRAMERI
  • Publication number: 20120204281
    Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 9, 2012
    Inventors: Clifford J. WOOLF, Tarek A. Samad
  • Publication number: 20120204280
    Abstract: This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and C. elegans Dragon family members are also disclosed.
    Type: Application
    Filed: February 28, 2012
    Publication date: August 9, 2012
    Inventors: Clifford J. Woolf, Tarek A. Samad
  • Publication number: 20120128624
    Abstract: Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
    Type: Application
    Filed: December 15, 2011
    Publication date: May 24, 2012
    Inventors: Zailin Yu, Yan Fu
  • Publication number: 20120129218
    Abstract: The present invention relates to a host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence. The host cell may further comprise a nucleic acid encoding a recombinant protein. The present invention also relates to a method for producing a recombinant protein by the host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 24, 2012
    Applicant: UNIVERSITY OF DELAWARE
    Inventors: KELVIN H. LEE, STEPHANIE HAMMOND
  • Publication number: 20120094906
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: April 19, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega